paper
review
immunomodul
activ
vaccin
evolv
past
year
although
initi
progress
isol
main
stream
immunolog
research
vaccin
develop
late
merg
main
stream
take
full
advantag
newest
develop
vaccinolog
first
immunomodul
vaccin
alreadi
market
variou
other
close
least
one
major
stumbl
block
immunomodul
activ
vaccin
inher
low
immunogen
self
antigen
number
case
solv
progress
made
veterinari
applic
help
formul
practic
rule
necessari
break
immunotoler
unlik
rule
use
design
better
immunomodul
vaccin
use
human
notabl
control
fertil
combat
tumour
paper
focu
activ
immun
self
molecul
notabl
hormon
activ
immun
foreign
molecul
deriv
instanc
pathogen
activ
vaccin
pathogen
one
appli
costeffect
prevent
practic
human
veterinari
medicin
one
outstand
properti
activ
vaccin
day
success
vaccin
develop
without
detail
refer
knowledg
immun
system
vaccin
found
way
market
sole
develop
focus
efficaci
target
anim
detail
analys
antigen
combin
modern
biotechnolog
techniqu
approach
extrem
success
led
whole
gener
new
vaccin
past
decad
thu
advanc
vaccin
develop
becom
depend
fundament
knowledg
antigen
structur
antigen
function
interact
antigen
receptor
antibodi
although
enorm
amount
literatur
avail
activ
immun
foreign
self
antigen
work
self
antigen
larg
ignor
work
activ
vaccin
foreign
antigen
nonetheless
side
may
learn
antiself
research
may
benefit
experi
foreign
antigen
antiforeign
research
may
benefit
experi
respect
activ
induct
antiself
immun
could
produc
new
lead
understand
spontan
auto
immun
diseas
develop
antitumour
vaccin
first
effort
studi
effect
activ
immun
hormon
done
lutein
hormon
lh
wakabayashi
tamaoki
quadri
et
al
pineda
et
al
subsequ
vast
array
protein
peptideand
steroid
hormon
tri
includ
folliclestimul
hormon
fsh
torjesen
sand
wick
nieschlag
alobaidi
et
al
human
chorion
gonadotrophn
hcg
talwar
et
al
thyroidstimul
hormon
tsh
melm
et
al
inhibin
henderson
et
al
scanlon
et
al
growth
hormon
gh
beatti
et
al
lutein
hormonereleas
hormon
lhrh
fraser
gunn
ladd
et
al
adam
adam
thau
hoskinson
et
al
vasopressin
kamoi
et
al
somatostatin
varner
et
al
testosteron
thomson
et
al
hillier
et
al
progesteron
kaushanski
et
al
mani
other
ohlson
et
al
yamada
et
al
bettencourt
et
al
ronayn
et
al
skinner
et
al
mettler
czuppon
travi
target
studi
manifold
includ
effort
control
fertil
provid
new
contracept
human
anim
lincoln
talwar
et
al
tallberg
et
al
reev
et
al
boost
product
farm
anim
increas
meat
qualiti
eas
anim
manag
adam
adam
finnerti
et
al
hoskinson
et
al
reev
et
al
prendivil
et
al
crow
et
al
crow
et
al
bonneau
et
al
combat
diseas
tallberg
et
al
thau
better
understand
endocrin
regul
bettencourt
et
al
martin
et
al
ohlson
et
al
safir
et
al
unexpectedli
activ
vaccin
hormon
fertil
axi
ie
target
lhrh
lh
fsh
hcg
wide
studi
potenti
modul
fertil
least
provid
new
contracept
procedur
fig
later
studi
extend
self
protein
involv
concept
reproduct
instanc
target
zona
pellucida
protein
sperm
antigen
etc
lincoln
prasad
rajalakshmi
talwar
talwar
et
al
within
avalanch
report
activ
immun
hormon
produc
last
year
two
hormon
fertil
axi
stand
one
small
peptid
hormon
lhrh
one
larg
protein
hormon
hcg
therefor
aspect
activ
vaccin
two
hormon
discuss
paper
vaccin
lhrh
studi
intens
lhrh
fulli
neutral
fertil
axi
mayb
shut
complet
fig
anim
product
would
allow
much
desir
altern
surgic
castrat
male
piglet
bull
meloen
et
al
finnerti
et
al
hoskinson
et
al
bonneau
et
al
furthermor
lhrh
vaccin
would
help
bring
cost
extens
farm
heifer
due
unwant
pregnanc
would
resolv
manag
problem
bull
would
form
use
tool
maintain
proper
ratio
anim
wildlif
reserv
would
eas
manag
problem
zoo
vaccin
probabl
practic
way
control
fertil
stray
anim
notabl
dog
fox
stray
anim
form
threat
human
health
form
reservoir
pathogen
microor
ganism
problem
present
develop
countri
also
increas
citi
develop
countri
carter
vaccin
lhrh
also
suggest
use
men
suffer
prostat
cancer
contracept
combin
testosteron
supplement
men
thau
ladd
furthermor
antilhrh
vaccin
recent
approv
commerci
veterinari
use
form
first
commerci
synthet
antipeptid
antihormon
vaccin
hoskinson
et
al
vaccin
hcg
capabl
provid
cheap
longlast
easi
appli
contracept
femal
especi
develop
world
combin
establish
vaccin
procedur
contracept
urgent
need
one
take
account
year
world
popul
increas
million
peopl
born
develop
countri
year
million
abort
perform
occur
unsaf
condit
lincoln
studi
activ
vaccin
hormon
posssibl
draw
gener
rule
respect
antigen
form
present
vaccin
formul
dose
adjuv
vaccin
procedur
evalu
efficaci
mode
action
possibl
side
effect
revers
contrast
foreign
antigen
self
antigen
poorli
immunogen
use
vaccin
reev
et
al
thu
sort
practic
approach
taken
overcom
lack
immunogen
major
one
coupl
antigen
carrier
molecul
eg
bovin
serum
albumin
bsa
keyhol
limpet
haemocyanin
klh
tetanu
toxoid
tt
chang
nativ
structur
hormon
molecul
either
chang
structur
eg
denatur
chang
configur
eg
applic
heterodim
truncat
dimer
molecul
appli
intact
molecul
differ
speci
small
antigen
like
lhrh
ten
amino
acid
vasopressin
nine
amino
acid
tend
poorli
immunogen
especi
self
antigen
molecul
need
coupl
other
increas
molecular
weight
make
suffici
foreign
normal
larg
protein
molecul
use
notabl
klh
tt
latter
molecul
even
use
human
protein
molecul
use
well
hoskinson
et
al
talwar
et
al
although
carrier
molecul
chosen
may
affect
efficaci
antigen
differ
way
particular
rule
known
except
one
ie
carrier
molecul
foreign
target
speci
coupl
normal
effect
use
bifunct
chemic
linker
like
mmaleimidobenzoylnhydroxysuccinimid
ester
mb
lerner
et
al
case
mb
linker
molecul
first
attach
free
amino
group
present
protein
mbsactiv
protein
link
free
sh
group
eg
cystein
present
peptid
protein
molecul
cystein
necessari
coupl
introduc
posit
within
amino
acid
sequenc
peptid
synthes
chemic
link
hook
either
end
peptid
posit
lhrh
effect
differ
linkag
posit
studi
mark
effect
observ
induc
immun
respons
goubau
et
al
b
silversid
et
al
ladd
howev
one
report
suggest
linkag
may
biolog
effect
ladd
instead
chemic
linkag
coupl
effect
genet
use
recombin
method
shown
recent
inhibin
ovalbumin
geari
reev
denatur
conform
chang
may
suffici
alter
antigen
site
self
molecul
induc
immun
system
respond
product
antibodi
cross
react
nativ
antigen
talwar
et
al
small
peptid
molecul
report
dimer
increas
immunogen
obtain
good
result
appli
tandem
repeat
amino
acid
sequenc
lhrh
fig
meloen
et
al
oonk
et
al
larg
molecul
like
hcg
fsh
contain
yand
psubunit
isol
subunit
use
eg
subunit
talwar
et
al
shahani
et
also
hetero
dimer
hybrid
molecul
appli
ie
artifici
peptid
use
monom
pehwsyglrpg
c
dimer
pehwsyglrpgqhwsyglrpg
tandem
repeat
nativ
amino
acid
sequenc
also
extra
ctermin
cy
ad
facilit
coupl
klh
pe
pyro
glutam
acid
dose
indic
amount
peptid
appli
b
vaccin
procedur
small
piglet
vaccin
twice
first
time
week
age
second
time
week
later
pig
slaughter
approx
week
old
normal
slaughter
age
c
success
vaccin
indic
size
testicl
slaughter
testicl
weigh
less
approx
g
cm
size
grossli
impair
function
produc
androstenon
one
steroid
respons
boar
taint
control
group
shamvaccin
anim
anim
tandem
group
small
testicl
contrast
monom
group
also
nonaffect
partial
affect
testicl
found
meloen
et
al
combin
asubunit
one
speci
combin
psubunit
anoth
speci
lerario
et
al
talwar
et
al
furthermor
use
ctermin
part
psubunit
appear
fairli
good
induc
antihcg
antibodi
thanavala
et
al
steven
ultim
approach
would
use
small
peptid
instead
intact
hormon
molecul
induc
immun
respons
inactiv
biolog
activ
intact
hormon
approach
particularli
appeal
allow
specif
target
immun
respons
product
cost
peptid
vaccin
low
instanc
case
fsh
might
allow
induct
specif
anti
psubunit
antibodi
crossreact
lh
would
result
cheap
peptid
vaccin
specif
neutral
fsh
leav
lh
activ
vaccin
would
ideal
contracept
vaccin
human
male
assum
fsh
neutral
spermatogenesi
block
libido
maintain
due
activ
lh
real
problem
approach
defin
amino
acid
sequenc
peptid
use
antifsh
vaccin
present
tri
defin
epitop
use
advanc
systemat
peptid
base
method
includ
pepscan
grootenhui
et
al
van
amerongen
et
al
westhoff
et
al
unpublish
result
approach
use
defin
use
immunogen
peptid
pathogen
includ
footandmouth
diseas
viru
fmdv
hiv
corona
virus
herp
viru
meloen
bartel
goudsmit
et
al
middeldorp
meloen
jacob
et
al
posthumu
et
al
langedijk
et
al
also
allow
us
develop
first
synthet
peptid
vaccin
give
full
protect
viral
diseas
canin
parvoviru
target
anim
langeveld
et
al
approach
use
amino
acid
sequenc
hormon
differ
speci
faulkner
neubauer
schone
melm
et
al
exampl
human
fsh
rabbit
readili
induc
antifsh
antibodi
specif
human
fsh
amino
acid
sequenc
human
fsh
rabbit
fsh
differ
approx
westhoff
person
commun
rose
et
al
appar
suffici
induc
antibodi
physic
form
antigen
present
immun
system
import
induc
immun
respons
especi
small
antigen
use
studi
peptid
deriv
foreign
antigen
known
looofold
effici
immun
respons
induc
peptid
present
nanomet
particl
ie
particl
size
nm
repetit
form
instanc
peptid
deriv
fmdv
coupl
klh
appli
dose
approx
pg
obtain
satisfactori
respons
bittl
et
al
fmdv
peptid
express
nterminu
hepat
b
core
protein
protein
spontan
form
nm
particl
particl
expos
nterminu
carri
fmdv
peptid
multipl
time
symmetr
fashion
pg
per
dose
need
appli
induc
immun
respons
obtain
approx
pg
klhcoupl
peptid
clark
et
al
exampl
highli
immunogen
combin
combin
peptid
hepat
b
surfac
antigen
delpeyroux
et
al
yeast
thi
protein
adam
et
al
small
nonenvelop
symmetr
virus
particl
nm
use
similar
minut
amount
obtain
good
respons
strongli
suggest
nanomet
particl
carri
small
antigen
symmetr
repetit
fashion
may
form
superb
immunogen
similarli
one
would
expect
peptid
properli
expos
iscom
immunostimul
particl
nm
engin
expos
antigen
repetit
manner
would
effect
carrier
protein
coupl
peptid
howev
although
rumour
promis
result
around
time
solid
publish
data
still
avail
much
also
gain
produc
molecul
carri
tandem
repeat
antigen
exampl
fmdv
peptid
express
tandem
galactosidas
although
less
immunogen
nanomet
particl
much
immunogen
similarli
express
singl
peptid
broekhuijsen
et
al
shown
lhrh
synthes
tandem
repeat
tandem
repeat
far
effect
nativ
monom
fig
meloen
et
al
oonk
et
al
take
ultim
molecul
one
could
think
singl
branch
synthet
molecul
carri
mani
lhrh
molecul
flegel
et
al
antigen
especi
self
antigen
without
adjuv
rare
induc
use
immun
respons
respons
often
suboptim
requir
larger
dose
multipl
inject
substanti
better
result
obtain
use
adjuv
ie
immunostimul
therefor
antigen
normal
mix
emulsifi
adjuv
wide
rang
substanc
formul
known
improv
induc
immun
respons
mode
action
well
known
subject
much
specul
howev
agre
adjuv
provid
two
major
function
one
reservoir
function
adjuv
store
antigen
releas
slowli
circul
thu
continu
stimul
immun
system
one
loos
defin
produc
local
inflamm
activ
non
specif
way
immun
system
instanc
induct
cytokin
recruit
cell
etc
steven
dalsgaard
et
al
one
least
effect
adjuv
aluminum
hydroxid
gel
onto
antigen
adsorb
adjuv
caus
advers
reaction
present
one
accept
use
human
hand
best
known
adjuv
freund
complet
adjuv
fca
miner
oilbas
adjuv
contain
cell
wall
extract
mycobacterium
tuberculosi
aqueou
antigen
solut
emulsifi
form
waterinoil
emuls
thought
provid
good
reservoir
also
activ
immun
system
well
howev
often
caus
unwant
side
reaction
inject
site
case
cattl
caus
anim
appear
posit
test
tuberculosi
therefor
use
human
rare
appli
anim
routin
basi
despit
still
use
often
laboratori
anim
form
less
golden
standard
adjuv
provid
upper
rang
effect
adjuv
well
defin
easi
obtain
use
thu
adjuv
normal
fall
rang
aluminum
hydroxid
lower
level
fca
upper
level
excel
concis
review
recent
publish
steven
use
adjuv
discuss
respect
antifertil
vaccin
claim
use
coupl
antigen
administ
slow
releas
particl
vaccin
efficaci
obtain
close
attain
fca
yet
fulli
accept
human
use
ideal
number
vaccin
kept
minimum
prefer
one
achiev
case
number
antidiseas
vaccin
veterinari
use
ultim
target
respect
antifertil
vaccin
steven
howev
even
best
contrast
foreign
antigen
vaccin
self
need
appli
least
twice
often
mani
time
obtain
full
efficaci
pose
anoth
practic
problem
two
vaccin
certain
circumst
still
accept
two
vaccin
serious
preclud
gener
applic
past
report
singl
vaccin
session
full
efficaci
laboratori
condit
achiev
howev
requir
mani
inject
site
time
practic
fraser
et
al
howev
recent
effect
one
shot
vaccin
gnrh
heifer
bull
pgf
heifer
develop
wj
enright
person
commun
furthermor
recent
data
suggest
one
shot
vaccin
may
possibl
well
use
mixtur
slow
releas
particl
deliv
primari
booster
vaccin
time
fast
dissolv
particl
provid
primari
antigen
dose
slowli
dissolv
particl
time
releas
content
booster
immun
requir
steven
protect
diseas
induc
vaccin
still
poorli
understood
ultim
protect
experi
target
anim
often
expens
ie
case
cattl
hors
virtual
imposs
human
much
effort
devot
defin
paramet
correl
protect
exampl
antibodi
neutral
viru
unfortun
best
paramet
correl
protect
restrict
experiment
condit
appli
anim
model
correl
sometim
found
negat
requir
protect
assay
target
anim
determin
efficaci
immunomodul
vaccin
except
instanc
immunocastr
vaccin
base
lhrh
may
differ
efficaci
rat
swine
therefor
immunocastr
trial
swine
need
done
swine
although
studi
much
labori
rat
anoth
import
gener
drawback
immunomodul
activ
vaccin
lack
adequ
respons
anim
treat
case
immunocastr
male
piglet
report
male
swine
fulli
regress
testicl
use
lhrh
vaccin
meloen
et
al
fig
use
anoth
lhrh
vaccin
pregnanc
heifer
prevent
hoskinson
et
al
pregnanc
rate
gener
low
especi
area
fertil
often
mandatori
anoth
aspect
must
consid
immunomodul
activ
vaccin
usual
appear
revers
ie
respons
disappear
ladd
et
al
although
desir
case
contracept
vaccin
human
also
pose
anoth
seriou
problem
revers
like
vari
individu
therefor
difficult
control
final
vaccin
accompani
unwant
side
effect
especi
case
vaccin
contracept
much
concern
express
possibl
occurr
unwant
side
effect
contrast
larg
varieti
concern
chard
howel
rose
et
al
berger
dirnhof
et
al
actual
data
human
nonexist
includ
ongo
trial
lincoln
scarc
data
anim
support
concern
ladd
et
al
upadhyay
et
al
giri
et
al
nevertheless
anim
system
excel
suit
studi
side
effect
involv
studi
lhrh
neuron
median
emin
swine
vaccin
lhrh
sometim
lhrhvaccin
anim
nerv
end
lhrh
neuron
appear
truncat
howev
lhrhvaccin
anim
effect
observ
furthermor
releas
hormon
appear
affect
molenaar
et
al
oonk
person
commun
whether
effect
transient
posit
neg
physiolog
signific
remain
seen
howev
crow
et
al
found
prostaglandin
vaccin
heifer
undesir
side
effect
could
occur
hand
potenti
worst
case
trial
respect
side
effect
report
activ
vaccin
cholesterol
result
actual
lower
cholesterol
level
without
appar
advers
side
effect
travi
surpris
cholesterol
integr
part
cell
membran
immun
system
evolv
recognis
effici
foreign
antigen
hand
system
learn
ignor
self
thu
tri
vaccin
self
like
tri
make
immun
system
someth
realli
design
inde
best
immun
reaction
self
gener
far
weaker
reaction
foreign
trial
error
number
method
evolv
trick
immun
system
mount
mostli
moder
respons
self
method
reli
alter
antigen
applic
strong
adjuv
repeat
vaccin
etc
describ
previous
superfici
mode
action
antiself
vaccin
appear
mediat
antibodi
howev
inconsist
exist
biolog
activ
vivo
vitro
measur
antibodi
respons
instanc
case
immunocastr
experi
pig
lhrh
vaccin
lhrh
bind
activ
antibodi
correl
well
biolog
activ
vivo
ie
sometim
fulli
regress
testicl
occur
presenc
low
antibodi
bind
activ
also
revers
seen
meloen
et
al
unpublish
observ
numer
explan
thought
exampl
one
could
argu
lhrh
bind
rather
inactiv
lhrh
activ
would
prefer
antibodi
paramet
measur
similarli
antihcg
vaccin
appear
highli
effect
neutral
activ
hcg
vivo
although
shown
antihcg
antibodi
neutral
vitro
lh
activ
hcg
dirnhof
et
al
clue
mode
action
antiself
vaccin
may
learn
data
obtain
basic
studi
induct
breakdown
immun
toler
well
studi
form
basi
auto
immun
diseas
particular
autoimmun
cell
often
via
cell
membran
expos
protein
focu
intens
interest
zinkernagel
et
al
sinha
et
al
induct
auto
immun
solubl
protein
appear
littl
relev
auto
immun
diseas
relev
immunomodul
recent
attract
attent
goodnow
et
al
latter
studi
suggest
antiself
antibodi
gener
averag
affin
nativ
self
antigen
antibodi
high
affin
self
may
occur
bcell
could
produc
antibodi
silenc
critic
role
suggest
origin
tcell
epitop
appar
borrow
foreign
carrier
protein
self
antigen
coupl
although
data
accord
result
obtain
trial
error
present
produc
new
lead
toward
design
better
immunomodul
vaccin
thu
gener
precis
mode
action
still
need
resolv
resolut
mode
action
may
help
design
effect
vaccin
immunomodul
activ
immun
may
help
improv
immunotherapi
base
tumor
vaccin
nossal
immunomodul
activ
vaccin
come
long
way
past
year
progress
slowli
isol
mainstream
immunolog
research
vaccin
develop
late
merg
mainstream
take
advantag
newest
technolog
develop
vaccinolog
involv
precis
epitop
map
beatti
et
al
westhoff
et
al
unpublish
observ
recombin
dna
approach
talwar
et
al
develop
deliveri
system
adjuv
systern
steven
use
concept
classic
vaccinolog
meloen
et
al
major
stumbl
block
success
vaccin
peptid
immunomodul
purpos
variat
respons
beween
anim
appear
solvabl
also
seriou
side
effect
predict
gener
yet
materi
inde
promis
use
medic
veterinari
vaccin
applic
process
realiz
